Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Qurgen Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT06873659
- Locations
- 🇨🇳
Beijing GoBroad Hospital, Beijing, Beijing Municipality, China
🇨🇳The First Hospital of Lanzhou University, Lanzhou, Gansu, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid TumorBreast CancerPancreatic CancerOvarian CancerColorectal Cancer
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Qurgen Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05989724
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center (BMDACC), Gilbert, Arizona, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
🇺🇸Carolina BioOncology Institute, Huntersville, North Carolina, United States
News
No news found